Actively Recruiting
A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity
Led by Eli Lilly and Company · Updated on 2026-04-20
150
Participants Needed
3
Research Sites
45 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main purpose of this study is to evaluate how different dose levels of brenipatide work and how safe they are in healthy people with overweight or obesity. The study will assess the effects of different doses given as subcutaneous (under the skin) injections. Participation in this study will last about 42 weeks.
CONDITIONS
Official Title
A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Are overtly healthy with no comorbidities related to body mass index (BMI), such as type 2 diabetes mellitus or unstable cardiovascular disease, as determined by medical evaluation
- Have a BMI within the range of 27.0 to 45.0 kilogram per square meter (kg/m²)
- Have no significant (not more than 5 percent [%]) self-reported weight gain or loss in the past 3 months prior to screening
You will not qualify if you...
- Have significant history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, dermatological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination; constituting a risk when taking the Investigational Medical Product (IMP); or interfering with the interpretation of data
- Have a prior diagnosis of type 1 or type 2 diabetes mellitus
- Have a history of acute or chronic pancreatitis
- Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2
- Have received a glucagon-like peptide-1 (GLP-1) receptor agonist, glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, GIP/GLP-1/glucagon receptor agonist, or amylin receptor agonist within 6 months prior to screening
- Have been treated with prescription and over-the-counter medications, or alternative remedies (including herbal/nutritional supplements), that promote weight loss within 6 months prior to screening
- Are pregnant or lactating
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Fortrea Clinical Research Unit - Daytona Beach
Daytona Beach, Florida, United States, 32117-5116
Actively Recruiting
2
Fortrea Clinical Research Unit
Dallas, Texas, United States, 75247
Actively Recruiting
3
Fortrea Clinical Research Unit Inc. - Madison
Madison, Wisconsin, United States, 53704
Actively Recruiting
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559)
CONTACT
P
Physicians interested in becoming principal investigators please contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here